EVOKE PHARMA, INC. Lease, Cost
EVOKE PHARMA, INC. reported Lease, Cost of $19.15 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2025-11-13
- EVOKE PHARMA, INC. lease, cost for the quarter ending 2025-09-30 was $19.15K, a 0.87% increase year-over-year.
- EVOKE PHARMA, INC. lease, cost for the quarter ending 2025-06-30 was $19.15K, a 0.95% increase year-over-year.
- EVOKE PHARMA, INC. lease, cost for the quarter ending 2025-03-31 was $20.11K, a 6.18% increase year-over-year.
- EVOKE PHARMA, INC. lease, cost for the quarter ending 2024-12-31 was $19.00K.
- EVOKE PHARMA, INC. lease, cost for fiscal 2024 was $75.88K, a 50.73% decline from fiscal 2023.
- EVOKE PHARMA, INC. lease, cost for fiscal 2023 was $154.03K.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-09-30 | $19.15K 10-Q · filed 2025-11-13 | $38.29K derived: sum of 2 quarters · filed 2025-11-13 | $58.40K 10-Q · filed 2025-11-13 | $77.40K derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | $19.15K 10-Q · filed 2025-08-14 | $39.25K 10-Q · filed 2025-08-14 | $58.25K derived: sum of 3 quarters · filed 2025-08-14 | $77.23K derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-03-31 | $20.11K 10-Q · filed 2025-05-13 | $39.11K derived: sum of 2 quarters · filed 2025-05-13 | $58.09K derived: sum of 3 quarters · filed 2025-11-13 | $77.05K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $37.98K derived: sum of 2 quarters · filed 2025-11-13 | $56.95K derived: sum of 3 quarters · filed 2025-11-13 | $75.88K 10-K · filed 2025-03-13 |
| 2024-09-30 | $18.98K 10-Q · filed 2025-11-13 | $37.95K derived: sum of 2 quarters · filed 2025-11-13 | $56.88K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $18.97K 10-Q · filed 2025-08-14 | $37.90K 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $18.94K 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $154.03K 10-K · filed 2025-03-13 |